Related Experiment Video
Updated: Jul 18, 2026

Inducible and Reversible Dominant-negative (DN) Protein Inhibition
Published on: January 7, 2019
Hypertension caused by transgenic overexpression of Rac1
Hamdy H Hassanain1, David Gregg, Maria Luisa Marcelo
1Department of Anesthesiology, Dorothy M. Davis Heart and Lung Institute, The Ohio State University, Columbus, Ohio 43210, USA. hamdy.hasssanain@osumc.edu
Abstract:
Reactive oxygen species, including superoxide, are important mediators of the pathophysiology of hypertension. In the vasculature, superoxide antagonizes nitric oxide (NO*), resulting in increased vascular tone. The GTP binding protein Rac regulates a wide variety of cellular functions, including the activation of NADPH oxidase, the major source of O2*-in the blood vessel wall. An hypothesis is that Rac1 may act as an important regulator of vascular O2*- production, contributing to the balance between O2*- and NO* and maintaining consequent homeostasis of blood pressure. To alter the activity of vascular NADPH oxidase, the authors developed a transgenic animal model that overexpresses the human cDNA of the constitutively active mutant of Rac1 (RacCA) in smooth muscle cells using the smooth muscle +/--actin promoter. The RacCA transgenic had excessive amounts of O2*- in the vessel wall that, which led to heightened production of peroxynitrite, as detected by increased protein nitration and reduced NO* levels. RacCA mice developed moderate hypertension, which was corrected by N-acetyl-L-cysteine (NAC). RacCA transgenic mice also developed left ventricular hypertrophy as a secondary effect of pressure overload. The data suggest that Rac1 is a critical regulator of the redox state of blood vessels and homeostasis of blood pressure.
Related Concept Videos
The Ras Gene
Ras is a superfamily...
Hypertension II: Pathophysiology
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Antihypertensive Drugs: Action of β1 Blockers
Hypertension and Regulation of Blood Pressure
Antihypertensive Drugs: Angiotensin II Receptor Blockers
